Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
Files in This Item:
|Aguirre_et_al_ADDR_2016_Researchgate.pdf||818.1 kB||Adobe PDF||Download|
|Title:||Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials||Authors:||Aguirre, Tanira A. S.
Brayden, David James
|Permanent link:||http://hdl.handle.net/10197/7801||Date:||15-Nov-2016||Abstract:||The development of oral dosage forms that allows absorption of therapeutic peptides to the systemic circulation is one of the greatest challenges for the pharmaceutical industry. Currently, a number of technologies including either mixtures of penetration enhancers or protease inhibitors and/or nanotechnology-based products are under clinical development. Typically, these formulations are presented in the form of enteric-coated tablets or capsules. Systems undergoing preclinical investigation include further advances in nanotechnology, including intestinal microneedle patches, as well as their combination with regional delivery to the colon. This review critically examines four selected promising oral peptide technologies at preclinical stage and the twelve that have progressed to clinical trials, as indicated in www.clinicaltrials.gov. We examined these technologies under the criteria of peptide selection, formulation design, system components and excipients, intestinal mechanism of action, efficacy in man, and safety issues. The conclusion is that most of the technologies in clinical trials are incremental rather than paradigm-shifting and that even the more clinically-advanced oral peptide drugs examples of oral bioavailability appear to yield oral bioavailability values of only 1-2% and are, therefore, only currently suitable for a limited range of peptides.||Funding Details:||European Commission - Seventh Framework Programme (FP7)||Type of material:||Journal Article||Publisher:||Elsevier||Copyright (published version):||2016 Elsevier||Keywords:||Oral peptides; Intestinal permeation enhancers; Therapeutic peptides; Peptide clinical trials; Oral nanotechnology||DOI:||10.1016/j.addr.2016.02.004||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Conway Institute Research Collection|
Veterinary Medicine Research Collection
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.